Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Common Equity (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Common Equity data on record, last reported at $24.7 million in Q4 2025.

  • For Q4 2025, Common Equity rose 350.94% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, up 350.94%, while the annual FY2025 figure was $24.7 million, 350.94% up from the prior year.
  • Common Equity reached $24.7 million in Q4 2025 per VRCA's latest filing, up from -$17.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $64.8 million in Q1 2023 and bottomed at -$34.1 million in Q3 2024.
  • Average Common Equity over 5 years is $20.6 million, with a median of $25.1 million recorded in 2022.
  • The widest YoY moves for Common Equity: up 350.94% in 2025, down 1331.83% in 2025.
  • A 5-year view of Common Equity shows it stood at $32.6 million in 2021, then increased by 22.78% to $40.0 million in 2022, then plummeted by 50.63% to $19.8 million in 2023, then plummeted by 149.89% to -$9.9 million in 2024, then surged by 350.94% to $24.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $24.7 million in Q4 2025, -$17.0 million in Q3 2025, and -$17.5 million in Q2 2025.